Professionally converted for accurate flowing-text e-book format reproduction, this series of reports deals with ongoing research by NASA into a risk reduction strategy for human space exploration and planned manned missions to Mars. Each report deals with a unique aspect of the human research needed to pursue long-duration missions. Many of the reports contain exclusive details about medical events impacting astronauts and cosmonauts on earlier flights, including Mir, Space Shuttle, and ISS Space Station missions.

Each risk Evidence Report contains a narrative discussion of the risk and its supporting evidence. All cited publicly-available references are listed at the end of the report. In addition, data that are significant or pivotal are summarized in text, tables, and charts in sufficient detail to allow the reader to critique the data and draw conclusions. The authors also indicate whether the data are from human, animal, or tissue, cellular, or molecular studies. The reports discuss evidence from both spaceflight (including biomedical research, Medical Requirements Integration Document [MRID] data, and operational performance or clinical observations) and ground (including space analog research and non-space analog biomedical or clinical research) research. When providing evidence from ground-based studies, authors discuss why these results are likely to be applicable in the space environment, offering any available validation information for the use of these ground-based systems.

Reports included in this compilation:

Evidence Report: Risk of Adverse Health Effects Due to Alterations in Host-Microorganism Interactions * Evidence Report: Risk of Incompatible Vehicle/Habitat Design * Evidence Report: Risk of Inadequate Design of Human and Automation/Robotic Integration

While preventative measures limit the presence of many medically significant microorganisms during spaceflight missions, microbial infection of crewmembers cannot be completely prevented. Spaceflight experiments over the past 50 years have demonstrated a unique microbial response to spaceflight culture, although the mechanisms behind those responses and their operational relevance were unclear. Thus, clearly defining and addressing the impact of spaceflight-associated alterations on host-microorganism interactions have not been addressed. In 2007, the operational importance of these microbial responses was emphasized, as the results of an experiment aboard STS-115 demonstrated that the enteric pathogen Salmonella enterica serovar Typhimurium (S. Typhimurium) increased in virulence in a murine model of infection. The experiment was reproduced in 2008 aboard STS-123, confirming this finding.

Crew health and performance is critical to successful human exploration beyond low Earth orbit. The Human Research Program (HRP) investigates and mitigates the highest risks to human health and performance, providing essential countermeasures and technologies for human space exploration. Risks include physiological and performance effects from hazards such as radiation, altered gravity, and hostile environments, as well as unique challenges in medical support, human factors, and behavioral health support. The HRP utilizes an Integrated Research Plan (IRP) to identify the approach and research activities planned to address these risks, which are assigned to specific Elements within the program.

The HRP utilizes various research platforms to conduct research. Ground research occurs in laboratories and analogs that mimic a portion of the spaceflight environment. In addition, the International Space Station (ISS) is used to conduct research requiring the unique environment of space.